Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00634348 · ClinicalTrials.gov registry record · Phase 4

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

A Phase 4 study of Schizophrenia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
256
Enrollment target
20
Study locations

NCT00634348 is a Phase 4 study of Schizophrenia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 256 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00634348, a Phase 4 study of Schizophrenia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
256 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder

Conditions Studied

Schizophrenia

Interventions

  • DRUG Ziprasidone
  • DRUG Aripiprazole

Study Locations (20)

California

  • Pfizer Investigational Site - Anaheim
  • Pfizer Investigational Site - Cerritos
  • Pfizer Investigational Site - Culver City
  • Pfizer Investigational Site - Garden Grove
  • Pfizer Investigational Site - Glendale
  • Pfizer Investigational Site - La Mesa
  • Pfizer Investigational Site - Newport Beach
  • Pfizer Investigational Site - Paramount
  • Pfizer Investigational Site - Riverside
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - Torrance
  • Pfizer Investigational Site - Upland

Maryland

  • Pfizer Investigational Site - Baltimore
  • Pfizer Investigational Site - Rockville

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Florida

  • Pfizer Investigational Site - Hialeah

Louisiana

  • Pfizer Investigational Site - Shreveport

Missouri

  • Pfizer Investigational Site - St Louis

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2004-04
Est. Completion 2005-03
Phase Phase 4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00634348

The ClinicalTrials.gov registry entry for NCT00634348 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Ziprasidone is the first listed.

NCT00634348 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Maryland, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00634348 about?

NCT00634348 is a clinical study titled "A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients". The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder

What is the current status of trial NCT00634348?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 256 participants. The study started on 2004-04. Estimated completion is 2005-03.

What conditions does trial NCT00634348 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00634348?

The interventions under investigation include: Ziprasidone (DRUG), Aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00634348?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00634348 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.